Jump to main content
Jump to site search


CO/light dual-activatable Ru(II)-conjugated oligomer agent for lysosome-targeted multimodal cancer therapeutics

Abstract

Stimuli-activatable and subcellular organelles-targeted agents with multimodal therapeutics is urgently desired for highly precise and effective cancer treatment. Herein, a CO/light dual-activatable Ru(II)-oligo-(thiophene ethynylene) (Ru-OTE) for lysosome-targeted cancer therapy is reported. Ru-OTE is prepared through coordination-driven self-assembly of a cationic conjugated oligomer (OTE-BN) ligand and a Ru(II) center. Upon the dual-triggering of internal gaseous signaling molecule CO and external light, Ru-OTE undergoes ligand substitution and releases OTE-BN followed by the dramatical fluorescence recovery, which could be used for monitoring drug delivery and imaging guided anticancer treatments. The released OTE-BN selectively accumulates in lysosomes, physically breaking their integrity. Then, the generated cytotoxic singlet oxygen (1O2) can cause severe lysosome damage, thus leading to cancer cell death through photodynamic therapy (PDT). Meanwhile, the release of Ru(II) core also suppresses cancer cell growth as an anticancer metal drug. The significant anticancer effect is realized by the multimodal therapeutics of physical disruption/PDT/chemotherapy. Importantly, Ru-OTE can be directly photo-activated by two-photon laser (800 nm) for efficient drug release and near infrared PDT. Furthermore, Ru-OTE with light irradiation inhibits tumor growth in the MDA-MB-231 breast tumor model with negligible side effects. This study demonstrates that the development of activatable Ru(II)-conjugated oligomer potential drug provides a new strategy for effective subcellular organelles-targeted multimodal cancer therapeutics.

Back to tab navigation

Supplementary files

Article information


Submitted
05 Mar 2021
Accepted
21 Jul 2021
First published
21 Jul 2021

This article is Open Access
All publication charges for this article have been paid for by the Royal Society of Chemistry

Chem. Sci., 2021, Accepted Manuscript
Article type
Edge Article

CO/light dual-activatable Ru(II)-conjugated oligomer agent for lysosome-targeted multimodal cancer therapeutics

M. Yang, H. Zhao, Z. Zhang, Q. Yuan, Q. Feng, X. Duan, S. Wang and Y. Tang, Chem. Sci., 2021, Accepted Manuscript , DOI: 10.1039/D1SC01317C

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.


Social activity

Search articles by author

Spotlight

Advertisements